- Cholangiocyte injury accounts for a quarter of drug-induced liver injury (DILI) cases and is associated with higher rates of morbidity and mortality than hepatocellular DILI (Chalasani et al., 2015).
- There are currently no methods to screen drugs for cholangiocyte toxicity potential at the lead candidate selection phase.
- Inhibition of multidrug resistance protein 3 (MDR3) by drugs has been shown to correlate with cholangiocyte injury and drug toxicity in humans.
- MDR3 mediates transport of phospholipids to the bile canaliculus. Inhibition of phospholipid transport reduces micelle formation resulting in free bile acids that can damage cholangiocytes.
- Clinically, cholangiocyte injury is defined as an isolated rise in serum alkaline phosphatase
By Guncha Taneja, Scott Siler, Brett Howell, Paul Watkins, Jeff Woodhead
Society of Toxicology 58th Annual Meeting and ToxExpo, March 10-14, 2019, Baltimore, MD